U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C20H30NO3.Br.H2O
Molecular Weight 430.3767
Optical Activity ( + / - )
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IPRATROPIUM BROMIDE

SMILES

CC(C)[N@@+]1(C)[C@@]2([H])CC[C@]1([H])C[C@@]([H])(C2)OC(=O)[C@@]([H])(CO)c3ccccc3.[Br-].O

InChI

InChIKey=KEWHKYJURDBRMN-KMYPTGJZSA-M
InChI=1S/C20H30NO3.BrH.H2O/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15;;/h4-8,14,16-19,22H,9-13H2,1-3H3;1H;1H2/q+1;;/p-1/t16-,17+,18+,19-,21?;;/m0../s1

HIDE SMILES / InChI

Molecular Formula HO
Molecular Weight 17.0073
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula BrH
Molecular Weight 80.9115
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C20H30NO3
Molecular Weight 332.4579
Charge 1
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: https://www.ncbi.nlm.nih.gov/mesh/68009241

Ipratropium (ipratropium bromide, ATROVENT® HFA) is a muscarinic antagonist structurally related to atropine but often considered safer and more effective for inhalation use. It is indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Ipratropium (ipratropium bromide, ATROVENT® HFA) is an anticholinergic (parasympatholytic) agent which, based on animal studies, appears to inhibit vagally-mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released at the neuromuscular junctions in the lung. Anticholinergics prevent the increases in intracellular concentration of Ca2+ which is caused by interaction of acetylcholine with the muscarinic receptors on bronchial smooth muscle.

CNS Activity

Curator's Comment:: "Topical intranasal ipratropium bromide has limited central nervous system penetration".

Originator

Sources: Svenska lakartidningen (1962), 59, 3384-5.
Curator's Comment:: Ravina, Enrique (2011). The evolution of drug discovery: from traditional medicines to modern drugs (1. Aufl. ed.). Weinheim: Wiley-VCH. p. 144.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ATROVENT HFA

Approved Use

ATROVENT HFA Inhalation Aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Launch Date

1101427200000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
33.5 pg/mL
20 μg 4 times / day multiple, respiratory
dose: 20 μg
route of administration: Respiratory
experiment type: MULTIPLE
co-administered: ALBUTEROL
IPRATROPIUM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
31.7 pg/mL
20 μg 4 times / day steady-state, respiratory
dose: 20 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered: ALBUTEROL
IPRATROPIUM plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE
food status: UNKNOWN
35.4 pg/mL
20 μg 4 times / day steady-state, respiratory
dose: 20 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered: ALBUTEROL
IPRATROPIUM plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1.04 pg × h/mL
20 μg 4 times / day multiple, respiratory
dose: 20 μg
route of administration: Respiratory
experiment type: MULTIPLE
co-administered: ALBUTEROL
IPRATROPIUM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
123 pg × h/mL
20 μg 4 times / day steady-state, respiratory
dose: 20 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered: ALBUTEROL
IPRATROPIUM plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE
food status: UNKNOWN
131 pg × h/mL
20 μg 4 times / day steady-state, respiratory
dose: 20 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered: ALBUTEROL
IPRATROPIUM plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2 h
20 μg 4 times / day multiple, respiratory
dose: 20 μg
route of administration: Respiratory
experiment type: MULTIPLE
co-administered: ALBUTEROL
IPRATROPIUM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
95.5%
20 μg 4 times / day multiple, respiratory
dose: 20 μg
route of administration: Respiratory
experiment type: MULTIPLE
co-administered: ALBUTEROL
IPRATROPIUM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
168 ug 3 times / day steady, respiratory
Highest studied dose
Dose: 168 ug, 3 times / day
Route: respiratory
Route: steady
Dose: 168 ug, 3 times / day
Sources:
unhealthy, 18 - 75 years
Health Status: unhealthy
Age Group: 18 - 75 years
Sex: M+F
Sources:
Disc. AE: Nasal disorder NOS, Nasal dryness...
AEs leading to
discontinuation/dose reduction:
Nasal disorder NOS (17%)
Nasal dryness (2%)
Epistaxis (2%)
Sources:
168 ug 3 times / day steady, respiratory
Highest studied dose
Dose: 168 ug, 3 times / day
Route: respiratory
Route: steady
Dose: 168 ug, 3 times / day
Sources:
unhealthy, 2 - 5 years
Health Status: unhealthy
Age Group: 2 - 5 years
Sex: M+F
Sources:
Disc. AE: Epistaxis...
AEs leading to
discontinuation/dose reduction:
Epistaxis (1 patient)
Sources:
84 ug 3 times / day steady, respiratory
Highest studied dose
Dose: 84 ug, 3 times / day
Route: respiratory
Route: steady
Dose: 84 ug, 3 times / day
Sources:
unhealthy, 2 - 5 years
Health Status: unhealthy
Age Group: 2 - 5 years
Sex: M+F
Sources:
Disc. AE: Epistaxis, Upper respiratory tract infection...
AEs leading to
discontinuation/dose reduction:
Epistaxis (1 patient)
Upper respiratory tract infection (1 patient)
Ear infection (1 patient)
Exacerbation of asthma (1 patient)
Sources:
200 ug single, respiratory
Highest studied dose
Dose: 200 ug
Route: respiratory
Route: single
Dose: 200 ug
Sources:
unhealthy, mean 40.7 years
Health Status: unhealthy
Age Group: mean 40.7 years
Sex: M+F
Sources:
Disc. AE: Nausea and vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea and vomiting (1 patient)
Sources:
42 ug 1 times / day steady, respiratory
Recommended
Dose: 42 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 42 ug, 1 times / day
Sources:
unhealthy, mean 42.6 years
Health Status: unhealthy
Age Group: mean 42.6 years
Sex: M+F
Sources:
Other AEs: Nasal disorder NOS...
Other AEs:
Nasal disorder NOS (19 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Nasal disorder NOS 17%
Disc. AE
168 ug 3 times / day steady, respiratory
Highest studied dose
Dose: 168 ug, 3 times / day
Route: respiratory
Route: steady
Dose: 168 ug, 3 times / day
Sources:
unhealthy, 18 - 75 years
Health Status: unhealthy
Age Group: 18 - 75 years
Sex: M+F
Sources:
Epistaxis 2%
Disc. AE
168 ug 3 times / day steady, respiratory
Highest studied dose
Dose: 168 ug, 3 times / day
Route: respiratory
Route: steady
Dose: 168 ug, 3 times / day
Sources:
unhealthy, 18 - 75 years
Health Status: unhealthy
Age Group: 18 - 75 years
Sex: M+F
Sources:
Nasal dryness 2%
Disc. AE
168 ug 3 times / day steady, respiratory
Highest studied dose
Dose: 168 ug, 3 times / day
Route: respiratory
Route: steady
Dose: 168 ug, 3 times / day
Sources:
unhealthy, 18 - 75 years
Health Status: unhealthy
Age Group: 18 - 75 years
Sex: M+F
Sources:
Epistaxis 1 patient
Disc. AE
168 ug 3 times / day steady, respiratory
Highest studied dose
Dose: 168 ug, 3 times / day
Route: respiratory
Route: steady
Dose: 168 ug, 3 times / day
Sources:
unhealthy, 2 - 5 years
Health Status: unhealthy
Age Group: 2 - 5 years
Sex: M+F
Sources:
Ear infection 1 patient
Disc. AE
84 ug 3 times / day steady, respiratory
Highest studied dose
Dose: 84 ug, 3 times / day
Route: respiratory
Route: steady
Dose: 84 ug, 3 times / day
Sources:
unhealthy, 2 - 5 years
Health Status: unhealthy
Age Group: 2 - 5 years
Sex: M+F
Sources:
Epistaxis 1 patient
Disc. AE
84 ug 3 times / day steady, respiratory
Highest studied dose
Dose: 84 ug, 3 times / day
Route: respiratory
Route: steady
Dose: 84 ug, 3 times / day
Sources:
unhealthy, 2 - 5 years
Health Status: unhealthy
Age Group: 2 - 5 years
Sex: M+F
Sources:
Exacerbation of asthma 1 patient
Disc. AE
84 ug 3 times / day steady, respiratory
Highest studied dose
Dose: 84 ug, 3 times / day
Route: respiratory
Route: steady
Dose: 84 ug, 3 times / day
Sources:
unhealthy, 2 - 5 years
Health Status: unhealthy
Age Group: 2 - 5 years
Sex: M+F
Sources:
Upper respiratory tract infection 1 patient
Disc. AE
84 ug 3 times / day steady, respiratory
Highest studied dose
Dose: 84 ug, 3 times / day
Route: respiratory
Route: steady
Dose: 84 ug, 3 times / day
Sources:
unhealthy, 2 - 5 years
Health Status: unhealthy
Age Group: 2 - 5 years
Sex: M+F
Sources:
Nausea and vomiting 1 patient
Disc. AE
200 ug single, respiratory
Highest studied dose
Dose: 200 ug
Route: respiratory
Route: single
Dose: 200 ug
Sources:
unhealthy, mean 40.7 years
Health Status: unhealthy
Age Group: mean 40.7 years
Sex: M+F
Sources:
Nasal disorder NOS 19 patients
42 ug 1 times / day steady, respiratory
Recommended
Dose: 42 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 42 ug, 1 times / day
Sources:
unhealthy, mean 42.6 years
Health Status: unhealthy
Age Group: mean 42.6 years
Sex: M+F
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 17.4 uM]
yes [IC50 2.5 uM]
yes [IC50 3.6 uM]
yes [IC50 30.5 uM]
yes [IC50 62.8 uM]
Drug as victim
PubMed

PubMed

TitleDatePubMed
Asthma medications and their potential adverse effects in the elderly: recommendations for prescribing.
2001
Anticholinergic therapy for bronchiectasis.
2001
Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants.
2001
Management of acute exacerbations of chronic obstructive pulmonary disease.
2001 Aug
Standard dose of inhaled albuterol significantly increases QT dispersion compared to low dose of albuterol plus ipratropium bromide therapy in moderate to severe acute asthma attacks in children.
2001 Dec
Randomized trial of the addition of ipratropium bromide to albuterol and corticosteroid therapy in children hospitalized because of an acute asthma exacerbation.
2001 Dec
Evidence-based treatments for acute asthma.
2001 Dec
Effect of ipratropium bromide on airway and pulmonary muscarinic receptors in a rat model of chronic obstructive pulmonary disease.
2001 Jan
Does adding ipratropium to salbutamol (albuterol) help children with asthma?
2001 Nov
Childhood asthma.
2001 Nov
Lower arrythmogenic risk of low dose albuterol plus ipratropium.
2001 Oct
Hospital-based management of acute asthmatic exacerbation: an assessment of physicians' behavior in Taiwan.
2001 Oct
The use of ipratropium bromide for the management of acute asthma exacerbation in adults and children: a systematic review.
2001 Oct
Drug therapy of childhood asthma.
2001 Sep
[Effect of anticholinergic therapy on myocardial reserve dynamics in patients with chronic obstructive bronchitis].
2001 Sep-Dec
Cold-induced rhinitis in skiers--clinical aspects and treatment with ipratropium bromide nasal spray: a randomized controlled trial.
2001 Sep-Oct
[Asthma follow-up after treatment of status asthmaticus in ICU Pneumonology Department in Warsaw Medical University].
2002
Prevention and treatment of respiratory syncytial virus bronchiolitis and postbronchiolitic wheezing.
2002
Role of cholinergic reflexes on the bronchoconstrictor reactivity to neurokinin a in allergic dogs.
2002
Heliox for treatment of exacerbations of chronic obstructive pulmonary disease.
2002
Histochemical and biochemical studies on the secretory mechanisms of some glands of guinea-pigs treated with histamine.
2002
Tiotropium bromide.
2002
[Pharmacodynamics of inhalation broncholytic agents introduced in a single dose by nebulizer in patients with severe exacerbation of bronchial asthma].
2002
Management of children with severe asthma exacerbation in the emergency department.
2002
Anticholinergic drugs for wheeze in children under the age of two years.
2002
Pharmacogenetics, pharmacogenomics and airway disease.
2002
Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease.
2002 Apr
Do bronchodilators have an effect on bronchiolitis?
2002 Apr
Intravenous versus oral corticosteroids for treatment of acute asthma exacerbations.
2002 Apr
Airways reactivity in patients with CF.
2002 Aug
Hospitalizations and mortality in the Lung Health Study.
2002 Aug 1
Clinical review: severe asthma.
2002 Feb
[Benefits of ipratropium bromide in the management of asthmatic crises in the emergency department].
2002 Feb
Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.
2002 Feb
Other option in bronchiolitis.
2002 Feb
Heterogeneity of release-inhibiting muscarinic autoreceptors in heart atria and urinary bladder: a study with M(2)- and M(4)-receptor-deficient mice.
2002 Feb
Dry powder ipratropium bromide is as safe and effective as metered-dose inhaler formulation: a cumulative dose-response study in chronic obstructive pulmonary disease patients.
2002 Feb
Treatment of patients hospitalized for exacerbations of chronic obstructive pulmonary disease: comparison of an oral/metered-dose inhaler regimen and an intravenous/nebulizer regimen.
2002 Feb
Effects of inhaled ipratropium bromide on breathing mechanics and gas exchange in exercising horses with chronic obstructive pulmonary disease.
2002 Jan
The incremental shuttle walking test in elderly people with chronic airflow limitation.
2002 Jan
Emergency department asthma: compliance with an evidence-based management algorithm.
2002 Jul
Management of acute, severe asthma in children.
2002 Jul-Aug
Hospital management of children with acute asthma exacerbations in Kuwait: adherence to international guidelines.
2002 Jul-Sep
Treatment and quality of life in patients with chronic obstructive pulmonary disease.
2002 Jun
The role of anticholinergics in acute asthma treatment: an evidence-based evaluation.
2002 Jun
Understanding and use of inhaler medication by asthmatics in specialty care in Trinidad: a study following development of Caribbean guidelines for asthma management and prevention.
2002 Jun
Mydriasis due to self-administered inhaled ipratropium bromide.
2002 Mar
In children hospitalized for asthma exacerbations, does adding ipratropium bromide to albuterol and corticosteroids improve outcome?
2002 Mar
[Effect of ipratropium bromide on calcium activated potassium channel in tracheal smooth muscle cells from chronically hypoxic rats].
2002 May
What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations?
2002 May
Patents

Sample Use Guides

The usual starting dose of ATROVENT® HFA is two inhalations four times a day. Patients may take additional inhalations as required; however, the total number of inhalations should not exceed 12 in 24 hours.
Route of Administration: Oral
In Vitro Use Guide
Ba 679 BR, atropine, and ipratropium bromide inhibited electrical field stimulation (EFS)-induced contraction with IC50 values of 0.17, 0.74, and 0.58 nM, respectively, in guinea pig trachea. Ba 679 BR had a slower onset and longer duration of action than atropine or ipratropium bromide (the times required to attain 50% of the maximum response were 34.8, 3.8, and 7.6 min, respectively, and the times required for 50% recovery of the response were 540, 31.6, and 81.2 min, respectively).
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:03:39 UTC 2021
Edited
by admin
on Fri Jun 25 21:03:39 UTC 2021
Record UNII
J697UZ2A9J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IPRATROPIUM BROMIDE
EP   MART.   ORANGE BOOK   USAN   USP   USP-RS   VANDF  
USAN  
Official Name English
IPRATROPIUM BROMIDE COMPONENT OF DUOVENT
Brand Name English
COMBIVENT COMPONENT IPRATROPIUM BROMIDE
Common Name English
IPRATROPIUM BROMIDE [VANDF]
Common Name English
IPRATROPIUM BROMIDE [USP MONOGRAPH]
Common Name English
IPRATROPIUM BROMIDE [USP-RS]
Common Name English
DUONEB COMPONENT IPRATROPIUM BROMIDE
Common Name English
IPRATROPIUM BROMIDE HYDRATE [JAN]
Common Name English
DUOVENT COMPONENT IPRATROPIUM BROMIDE
Brand Name English
SCH 1000-BR-MONOHYDRATE
Code English
IPRATROPIUM BROMIDE COMPONENT OF COMBIVENT
Common Name English
IPRATROPIUM BROMIDE COMPONENT OF DUONEB
Common Name English
8-AZONIABICYCLO(3.2.1)OCTANE, 3-(3-HYDROXY-1-OXO-2-PHENYLPROPOXY)-8-METHYL-8-(1-METHYLETHYL)-, BROMIDE, MONOHYDRATE(ENDO,SYN)-, (+/-)-
Common Name English
IPRATROPIUM BROMIDE [ORANGE BOOK]
Common Name English
NSC-759613
Code English
IPRATROPIUM BROMIDE [MART.]
Common Name English
IPRATROPIUM BROMIDE MONOHYDRATE [WHO-DD]
Common Name English
IPRATROPIUM BROMIDE HYDRATE
JAN  
Common Name English
(8R)-3.ALPHA.-HYDROXY-8-ISOPROPYL-1.ALPHA.H,5.ALPHA.H-TROPANIUM BROMIDE (+/-)-TROPATE MONOHYDRATE
Common Name English
SCH-1000-BR-
Code English
ATROVENT
Brand Name English
IPRATROPIUM BROMIDE [USAN]
Common Name English
IPRATROPIUM BROMIDE [EP MONOGRAPH]
Common Name English
Classification Tree Code System Code
WHO-VATC QR01AX03
Created by admin on Fri Jun 25 21:03:39 UTC 2021 , Edited by admin on Fri Jun 25 21:03:39 UTC 2021
WHO-ATC R03AL01
Created by admin on Fri Jun 25 21:03:39 UTC 2021 , Edited by admin on Fri Jun 25 21:03:39 UTC 2021
WHO-ATC R03AL02
Created by admin on Fri Jun 25 21:03:39 UTC 2021 , Edited by admin on Fri Jun 25 21:03:39 UTC 2021
NCI_THESAURUS C319
Created by admin on Fri Jun 25 21:03:39 UTC 2021 , Edited by admin on Fri Jun 25 21:03:39 UTC 2021
NCI_THESAURUS C29704
Created by admin on Fri Jun 25 21:03:39 UTC 2021 , Edited by admin on Fri Jun 25 21:03:39 UTC 2021
WHO-VATC QR03AL01
Created by admin on Fri Jun 25 21:03:39 UTC 2021 , Edited by admin on Fri Jun 25 21:03:39 UTC 2021
WHO-VATC QR03BB01
Created by admin on Fri Jun 25 21:03:39 UTC 2021 , Edited by admin on Fri Jun 25 21:03:39 UTC 2021
WHO-ATC R03BB01
Created by admin on Fri Jun 25 21:03:39 UTC 2021 , Edited by admin on Fri Jun 25 21:03:39 UTC 2021
WHO-ATC R01AX03
Created by admin on Fri Jun 25 21:03:39 UTC 2021 , Edited by admin on Fri Jun 25 21:03:39 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 25.1
Created by admin on Fri Jun 25 21:03:39 UTC 2021 , Edited by admin on Fri Jun 25 21:03:39 UTC 2021
WHO-VATC QR03AL02
Created by admin on Fri Jun 25 21:03:39 UTC 2021 , Edited by admin on Fri Jun 25 21:03:39 UTC 2021
Code System Code Type Description
EVMPD
SUB22932
Created by admin on Fri Jun 25 21:03:39 UTC 2021 , Edited by admin on Fri Jun 25 21:03:39 UTC 2021
PRIMARY
FDA UNII
J697UZ2A9J
Created by admin on Fri Jun 25 21:03:39 UTC 2021 , Edited by admin on Fri Jun 25 21:03:39 UTC 2021
PRIMARY
USP_CATALOG
1347507
Created by admin on Fri Jun 25 21:03:39 UTC 2021 , Edited by admin on Fri Jun 25 21:03:39 UTC 2021
PRIMARY USP-RS
NCI_THESAURUS
C29128
Created by admin on Fri Jun 25 21:03:39 UTC 2021 , Edited by admin on Fri Jun 25 21:03:39 UTC 2021
PRIMARY
DRUG BANK
DBSALT000208
Created by admin on Fri Jun 25 21:03:39 UTC 2021 , Edited by admin on Fri Jun 25 21:03:39 UTC 2021
PRIMARY
RXCUI
203212
Created by admin on Fri Jun 25 21:03:39 UTC 2021 , Edited by admin on Fri Jun 25 21:03:39 UTC 2021
ALTERNATIVE
EPA CompTox
66985-17-9
Created by admin on Fri Jun 25 21:03:39 UTC 2021 , Edited by admin on Fri Jun 25 21:03:39 UTC 2021
PRIMARY
CAS
66985-17-9
Created by admin on Fri Jun 25 21:03:39 UTC 2021 , Edited by admin on Fri Jun 25 21:03:39 UTC 2021
PRIMARY
ChEMBL
CHEMBL1621597
Created by admin on Fri Jun 25 21:03:39 UTC 2021 , Edited by admin on Fri Jun 25 21:03:39 UTC 2021
PRIMARY
WIKIPEDIA
IPRATROPIUM BROMIDE
Created by admin on Fri Jun 25 21:03:39 UTC 2021 , Edited by admin on Fri Jun 25 21:03:39 UTC 2021
PRIMARY
RXCUI
1309404
Created by admin on Fri Jun 25 21:03:39 UTC 2021 , Edited by admin on Fri Jun 25 21:03:39 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
TRANSPORTER -> INHIBITOR
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
USP
Related Record Type Details
ACTIVE MOIETY